England and Wales
(State or Other Jurisdiction
of Incorporation)
|
|
001-37599
(Commission
File Number)
|
|
98-1268150
(IRS Employer
Identification No.)
|
Exhibit 99.1
|
Press Release issued by LivaNova PLC dated March 1, 2017
|
LivaNova PLC
|
|
Date: March 1, 2017
|
By:/s/ Catherine Moroz
|
Name: Catherine Moroz
|
|
Title: Company Secretary
|
|
Exhibit No.
|
|
Description
|
99.1
|
Press Release issued by LivaNova PLC dated March 1, 2017
|
Three Months Ended December 31,
|
% Change
|
Constant Currency % Change
|
||||
In $ millions
|
2016
|
2015
|
||||
Cardiopulmonary
|
$124.7
|
$130.0
|
(4.0
|
%)
|
(3.4
|
%)
|
Heart Valves
|
34.0
|
34.9
|
(2.6
|
%)
|
(2.2
|
%)
|
Cardiac Surgery
|
158.7
|
164.9
|
(3.7
|
%)
|
(3.2
|
%)
|
Cardiac Rhythm Management
|
61.0
|
60.7
|
0.6
|
%
|
1.3
|
%
|
Neuromodulation
|
90.5
|
91.5
|
(1.1
|
%)
|
(0.3
|
%)
|
Other
|
0.4
|
0.9
|
(54.7
|
%)
|
(53.5
|
%)
|
Total Net Sales
|
$310.6
|
$318.0
|
(2.3
|
%)
|
(1.6
|
%)
|
•
|
Numbers may not add due to rounding. Constant currency % change is considered a non-GAAP metric.
|
Twelve Months Ended December 31,
|
% Change
|
Constant Currency % Change
|
||||
In $ millions
|
2016
|
2015
|
||||
Cardiopulmonary
|
$474.4
|
$476.4 |
(0.4
|
%)
|
(0.1
|
%)
|
Heart Valves
|
137.3
|
140.2
|
(2.1
|
%)
|
(1.6
|
%)
|
Cardiac Surgery
|
611.7
|
616.6
|
(0.8
|
%)
|
(0.5
|
%)
|
Cardiac Rhythm Management
|
249.1
|
260.5
|
(4.4
|
%)
|
(4.7
|
%)
|
Neuromodulation
|
351.4
|
324.3
|
8.3
|
%
|
8.8
|
%
|
Other
|
1.7
|
3.2
|
(45.4
|
%)
|
(42.6
|
%)
|
Total Net Sales
|
$1,213.9
|
$1,204.6 |
0.8
|
%
|
1.0
|
%
|
•
|
Numbers may not add due to rounding. Constant currency % change is considered a non-GAAP metric.
|
Earnings Per Share
|
|||
Estimated merger and integration charges
|
$0.05
|
-
|
$0.08
|
Estimated charges for restructuring
|
$0.29
|
-
|
$0.33
|
Amortization of intangible assets related to purchase price accounting
|
$0.80
|
||
Estimated charges related to equity compensation
|
$0.29
|
-
|
$0.33
|
For more information, please visit www.LivaNova.com, or contact:
Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications Phone: +1 (281) 228-7262 Fax: +1 (281) 218-9332 e-mail: Corporate.Communications@LivaNova.com |
LIVANOVA PLC
|
||||||||||||||
QUARTERLY SALES TREND BY BUSINESS UNIT
|
||||||||||||||
U.S. dollars in millions, CONSTANT CURRENCY
|
||||||||||||||
1Q15
|
2Q15
|
3Q15
|
4Q15
|
FY15
|
1Q16
|
2Q16
|
3Q16
|
4Q16
|
FY16
|
4Q16 vs. 4Q15
|
FY16 vs. FY15
|
|||
Net Sales
|
||||||||||||||
Cardio Pulmonary
|
$107.5
|
$125.9
|
$113.0
|
$130.0
|
$476.4
|
$113.4
|
$123.6
|
$113.3
|
$125.5
|
$475.8
|
(3.4
|
%)
|
(0.1
|
%)
|
Heart Valves
|
34.7
|
36.4
|
34.2
|
34.9
|
140.2
|
33.4
|
37.0
|
33.4
|
34.2
|
137.9
|
(2.2
|
%)
|
(1.6
|
%)
|
Cardiac Surgery Total
|
142.2
|
162.3
|
147.2
|
164.9
|
616.6
|
146.8
|
160.7
|
146.6
|
159.6
|
613.7
|
(3.2
|
%)
|
(0.5
|
%)
|
CRM
|
70.4
|
75.6
|
53.9
|
60.7
|
260.5
|
62.9
|
68.1
|
55.8
|
61.4
|
248.2
|
1.3
|
%
|
(4.7
|
%)
|
Neuromodulation
|
70.1
|
78.4
|
84.3
|
91.5
|
324.3
|
81.6
|
90.1
|
90.0
|
91.2
|
353.0
|
(0.3
|
%)
|
8.8
|
%
|
Other
|
0.7
|
0.7
|
0.8
|
0.9
|
3.2
|
0.5
|
0.4
|
0.5
|
0.4
|
1.8
|
(53.5
|
%)
|
(42.6
|
%)
|
Total
|
$283.4
|
$317.1
|
$286.1
|
$318.0
|
$1,204.6
|
$291.8
|
$319.3
|
$292.9
|
$312.8
|
$1,216.8
|
(1.6
|
%)
|
1.0
|
%
|
LIVANOVA PLC
|
||||||||||||||
QUARTERLY SALES TREND BY BUSINESS UNIT
|
||||||||||||||
U.S. dollars in millions, REPORTED
|
||||||||||||||
1Q15
|
2Q15
|
3Q15
|
4Q15
|
FY15
|
1Q16
|
2Q16
|
3Q16
|
4Q16
|
FY16
|
4Q16 vs. 4Q15
|
FY16 vs. FY15
|
|||
Net Sales
|
||||||||||||||
Cardio Pulmonary
|
$107.5
|
$125.9
|
$113.0
|
$130.0
|
$476.4
|
$110.9
|
$124.0
|
$114.8
|
$124.7
|
$474.4
|
(4.0
|
%)
|
(0.4
|
%)
|
Heart Valves
|
34.7
|
36.4
|
34.2 |
34.9
|
140.2
|
32.5
|
37.1
|
33.7
|
34.0
|
137.3
|
(2.6
|
%)
|
(2.1
|
%)
|
Cardiac Surgery Total
|
142.2
|
162.3
|
147.2 |
164.9
|
616.6
|
143.4
|
161.1
|
148.5
|
158.7
|
611.7
|
(3.7
|
%)
|
(0.8
|
%)
|
CRM
|
70.4
|
75.6
|
53.9 |
60.7
|
260.5
|
61.7
|
69.6
|
56.8
|
61.0
|
249.1
|
0.6
|
%
|
(4.4
|
%)
|
Neuromodulation
|
70.1
|
78.4
|
84.3 |
91.5
|
324.3
|
81.4
|
90.0
|
89.5
|
90.5
|
351.4
|
(1.1
|
%)
|
8.3
|
%
|
Other
|
0.7
|
0.7
|
0.8 |
0.9
|
3.2
|
0.4
|
0.4
|
0.5
|
0.4
|
1.7
|
(54.7
|
%)
|
(45.4
|
%)
|
Total
|
$283.4
|
$317.1
|
$286.1
|
$318.0
|
$1,204.6
|
$287.0
|
$321.0
|
$295.3
|
$310.6
|
$1,213.9
|
(2.3
|
%)
|
0.8
|
%
|
LIVANOVA PLC
|
||||||||||||||
QUARTERLY SALES TREND BY REGION
|
||||||||||||||
U.S. dollars in millions, REPORTED
|
||||||||||||||
1Q15
|
2Q15
|
3Q15
|
4Q15
|
FY15
|
1Q16
|
2Q16
|
3Q16
|
4Q16
|
FY16
|
4Q16 vs. 4Q15
|
FY16 vs. FY15
|
|||
Cardio Pulmonary
|
||||||||||||||
US
|
$32.9
|
$43.0
|
$39.8
|
$45.9
|
$161.7
|
$34.5
|
$39.2
|
$39.4
|
$41.3
|
$154.4
|
(10.0
|
%)
|
(4.5
|
%)
|
Europe
|
33.6
|
37.1
|
31.7
|
35.6 | 137.9 |
31.5
|
34.9
|
28.3
|
33.8
|
128.5
|
(4.9
|
%)
|
(6.8
|
%)
|
Rest of World
|
41.0
|
45.9
|
41.5
|
48.5 | 176.9 |
45.0
|
49.9
|
47.2
|
49.5
|
191.5
|
2.2
|
%
|
8.3
|
%
|
Total
|
107.5
|
125.9
|
113.0
|
130.0 | 476.4 |
110.9
|
124.0
|
114.8
|
124.7
|
474.4
|
(4.0
|
%)
|
(0.4
|
%)
|
Heart Valve
|
||||||||||||||
US
|
6.7
|
6.7
|
6.1
|
5.8 | 25.2 |
6.5
|
7.1
|
7.4
|
6.8
|
27.7
|
17.4
|
%
|
9.8
|
%
|
Europe
|
12.8
|
13.0
|
10.3
|
10.9 | 46.9 |
11.4
|
12.5
|
9.7
|
10.7
|
44.3
|
(1.6
|
%)
|
(5.5
|
%)
|
Rest of World
|
15.2
|
16.8
|
17.8
|
18.2 | 68.1 |
14.7
|
17.5
|
16.6
|
16.5
|
65.3
|
(9.6
|
%)
|
(4.1
|
%)
|
Total
|
34.7
|
36.4
|
34.2
|
34.9 | 140.2 |
32.5
|
37.1
|
33.7
|
34.0
|
137.3
|
(2.6
|
%)
|
(2.1
|
%)
|
Cardiac Surgery
|
||||||||||||||
US
|
39.6
|
49.6
|
45.9
|
51.7 | 186.9 |
40.9
|
46.3
|
46.8
|
48.1
|
182.1
|
(6.9
|
%)
|
(2.5
|
%)
|
Europe
|
46.3
|
50.0
|
41.9
|
46.5 | 184.8 |
42.9
|
47.4
|
38.0
|
44.5
|
172.8
|
(4.1
|
%)
|
(6.5
|
%)
|
Rest of World
|
56.2
|
62.7
|
59.3
|
66.7 | 245.0 |
59.7
|
67.4
|
63.7
|
66.1
|
256.8
|
(1.0
|
%)
|
4.8
|
%
|
Total
|
142.2
|
162.3
|
147.2
|
164.9 | 616.6 |
143.4
|
161.1
|
148.5
|
158.7
|
611.7
|
(3.7
|
%)
|
(0.8
|
%)
|
CRM
|
||||||||||||||
US
|
4.5
|
3.9
|
3.9
|
3.1 | 15.5 |
3.0
|
2.3
|
2.2
|
2.5
|
9.9
|
(20.9
|
%)
|
(36.0
|
%)
|
Europe
|
51.0
|
52.3
|
44.8
|
50.5 | 198.6 |
50.0
|
54.4
|
44.7
|
48.1
|
197.2
|
(4.8
|
%)
|
(0.7
|
%)
|
Rest of World
|
14.9
|
19.4
|
5.1
|
7.0 | 46.4 |
8.7
|
12.9
|
9.8
|
10.5
|
41.9
|
49.1
|
%
|
(9.7
|
%)
|
Total
|
70.4
|
75.6
|
53.9
|
60.7 | 260.5 |
61.7
|
69.6
|
56.8
|
61.0
|
249.1
|
0.6
|
%
|
(4.4
|
%)
|
Neuromodulation
|
||||||||||||||
US
|
57.5
|
63.6
|
70.9
|
76.8 | 268.8 |
70.2
|
75.8
|
74.9
|
77.6
|
298.5
|
1.0
|
%
|
11.0
|
%
|
Europe
|
8.7
|
8.9
|
8.4
|
9.2 | 35.2 |
6.4
|
9.4
|
8.5
|
7.7
|
31.9
|
(15.8
|
%)
|
(9.2
|
%)
|
Rest of World
|
3.9
|
6.0
|
4.9
|
5.5 | 20.3 |
4.8
|
4.9
|
6.2
|
5.2
|
21.0
|
(5.2
|
%)
|
3.3
|
%
|
Total
|
70.1
|
78.4
|
84.3
|
91.5 | 324.3 |
81.4
|
90.0
|
89.5
|
90.5
|
351.4
|
(1.1
|
%)
|
8.3
|
%
|
Other
|
||||||||||||||
US
|
—
|
—
|
—
|
---- | ---- |
—
|
—
|
—
|
—
|
—
|
N/A
|
N/A
|
||
Europe
|
—
|
—
|
—
|
0.2 | 0.3 |
0.1
|
0.1
|
—
|
—
|
0.1
|
N/A
|
N/A
|
||
Rest of World
|
0.7
|
0.7
|
0.8
|
0.7 | 2.9 |
0.4
|
0.3
|
0.5
|
0.4
|
1.6
|
(36.2
|
%)
|
(44.1
|
%)
|
Total
|
0.7
|
0.7
|
0.8
|
0.9 | 3.2 |
0.4
|
0.4
|
0.5
|
0.4
|
1.7
|
(54.7
|
%)
|
(45.4
|
%)
|
Total
|
||||||||||||||
US
|
101.6
|
117.1
|
120.8
|
131.6 | 471.2 |
114.1
|
124.4
|
123.8
|
128.1
|
490.5
|
(2.7
|
%)
|
4.1
|
%
|
Europe
|
106.1
|
111.2
|
95.2
|
106.4 | 418.8 |
99.3
|
111.2
|
91.2
|
100.3
|
402.1
|
(5.7
|
%)
|
(4.0
|
%)
|
Rest of World
|
75.7
|
88.8
|
70.2
|
79.9 | 314.6 |
73.5
|
85.4
|
80.2
|
82.2
|
321.4
|
2.8
|
%
|
2.1
|
%
|
Total
|
$283.4
|
$317.1
|
$286.1
|
$318.0
|
$1,204.6
|
$287.0
|
$321.0
|
$295.3
|
$310.6
|
$1,213.9
|
(2.3
|
%)
|
0.8
|
%
|
LIVANOVA PLC
|
||||||||||||||||||||||||
QUARTERLY SALES TREND BY REGION
|
||||||||||||||||||||||||
U.S. dollars in millions, CONSTANT CURRENCY
|
||||||||||||||||||||||||
1Q15
|
2Q15
|
3Q15
|
4Q15
|
FY15
|
1Q16
|
2Q16
|
3Q16
|
4Q16
|
FY16
|
4Q16 vs. 4Q15
|
FY16 vs. FY15
|
|||||||||||||
Cardio Pulmonary
|
||||||||||||||||||||||||
US
|
$32.9
|
$43.0
|
$39.8
|
$45.9
|
$161.7
|
$34.5
|
$39.2
|
$39.4
|
$41.3
|
$154.4
|
(10.0
|
%)
|
(4.5
|
%)
|
||||||||||
Europe
|
33.6
|
37.1
|
31.7
|
35.6
|
137.9
|
32.4
|
34.6
|
28.8
|
35.4
|
131.1
|
(0.5
|
%)
|
(4.9
|
%)
|
||||||||||
Rest of World
|
41.0
|
45.9
|
41.5
|
48.5
|
176.9
|
46.6
|
49.8
|
45.1
|
48.8
|
190.3
|
0.6
|
%
|
7.6
|
%
|
||||||||||
Total
|
107.5
|
125.9
|
113.0
|
130.0
|
476.4
|
113.4
|
123.6
|
113.3
|
125.5
|
475.8
|
(3.4
|
%)
|
(0.1
|
%)
|
||||||||||
Heart Valve
|
||||||||||||||||||||||||
US
|
6.7
|
6.7
|
6.1
|
5.8
|
25.2
|
6.5
|
7.1
|
7.4
|
6.8
|
27.7
|
17.4
|
%
|
9.8
|
%
|
||||||||||
Europe
|
12.8
|
13.0
|
10.3
|
10.9
|
46.9
|
11.7
|
12.4
|
9.9
|
11.1
|
45.0
|
1.7
|
%
|
(4.0
|
%)
|
||||||||||
Rest of World
|
15.2
|
16.8
|
17.8
|
18.2
|
68.1
|
15.2
|
17.6
|
16.1
|
16.3
|
65.2
|
(10.6
|
%)
|
(4.3
|
%)
|
||||||||||
Total
|
34.7
|
36.4
|
34.2
|
34.9
|
140.2
|
33.4
|
37.0
|
33.4
|
34.2
|
137.9
|
(2.2
|
%)
|
(1.6
|
%)
|
||||||||||
Cardiac Surgery
|
||||||||||||||||||||||||
US
|
39.6
|
49.6
|
45.9
|
51.7
|
186.9
|
40.9
|
46.3
|
46.8
|
48.1
|
182.1
|
(6.9
|
%)
|
(2.5
|
%)
|
||||||||||
Europe
|
46.3
|
50.0
|
41.9
|
46.5
|
184.8
|
44.0
|
47.0
|
38.7
|
46.5
|
176.1
|
0.0%
|
(4.7
|
%)
|
|||||||||||
Rest of World
|
56.2
|
62.7
|
59.3
|
66.7
|
245.0
|
61.8
|
67.4
|
61.2
|
65.1
|
255.5
|
(2.5
|
%)
|
4.3
|
%
|
||||||||||
Total
|
142.2
|
162.3
|
147.2
|
164.9
|
616.6
|
146.8
|
160.7
|
146.6
|
159.6
|
613.7
|
(3.2
|
%)
|
(0.5
|
%)
|
||||||||||
CRM
|
||||||||||||||||||||||||
US
|
4.5
|
3.9
|
3.9
|
3.1
|
15.5
|
3.0
|
2.3
|
2.2
|
2.5
|
9.9
|
(20.9
|
%)
|
(36.0
|
%)
|
||||||||||
Europe
|
51.0
|
52.3
|
44.8
|
50.5
|
198.6
|
51.2
|
53.5
|
44.8
|
49.2
|
198.7
|
(2.7
|
%)
|
0.1
|
%
|
||||||||||
Rest of World
|
14.9
|
19.4
|
5.1
|
7.0
|
46.4
|
8.7
|
12.3
|
8.8
|
9.8
|
39.6
|
39.7
|
%
|
(14.7
|
%)
|
||||||||||
Total
|
70.4
|
75.6
|
53.9
|
60.7
|
260.5
|
62.9
|
68.1
|
55.8
|
61.4
|
248.2
|
1.3
|
%
|
(4.7
|
%)
|
||||||||||
Neuromodulation
|
||||||||||||||||||||||||
US
|
57.5
|
63.6
|
70.9
|
76.8
|
268.8
|
70.2
|
75.8
|
74.9
|
77.6
|
298.5
|
1.0
|
%
|
11.0
|
%
|
||||||||||
Europe
|
8.7
|
8.9
|
8.4
|
9.2
|
35.2
|
6.6
|
9.4
|
9.0
|
8.4
|
33.5
|
(8.2
|
%)
|
(4.9
|
%)
|
||||||||||
Rest of World
|
3.9
|
6.0
|
4.9
|
5.5
|
20.3
|
4.8
|
4.9
|
6.1
|
5.2
|
21.1
|
(4.5
|
%)
|
3.6
|
%
|
||||||||||
Total
|
70.1
|
78.4
|
84.3
|
91.5
|
324.3
|
81.6
|
90.1
|
90.0
|
91.2
|
353.0
|
(0.3
|
%)
|
8.8
|
%
|
||||||||||
Other
|
||||||||||||||||||||||||
US
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
N/A
|
N/A
|
||||||||||||
Europe
|
—
|
—
|
—
|
0.2
|
0.3
|
0.1
|
0.1
|
—
|
—
|
0.1
|
N/A
|
N/A
|
||||||||||||
Rest of World
|
0.7
|
0.7
|
0.8
|
0.7
|
2.9
|
0.5
|
0.3
|
0.5
|
0.4
|
1.7
|
(34.7
|
%)
|
(41.1
|
%)
|
||||||||||
Total
|
0.7
|
0.7
|
0.8
|
0.9
|
3.2
|
0.5
|
0.4
|
0.5
|
0.4
|
1.8
|
(53.5
|
%)
|
(42.6
|
%)
|
||||||||||
Total
|
||||||||||||||||||||||||
US
|
101.6
|
117.1
|
120.8
|
131.6
|
471.2
|
114.1
|
124.4
|
123.8
|
128.1
|
490.5
|
(2.7
|
%)
|
4.1
|
%
|
||||||||||
Europe
|
106.1
|
111.2
|
95.2
|
106.4
|
418.8
|
101.9
|
110.0
|
92.5
|
104.0
|
408.4
|
(2.2
|
%)
|
(2.5
|
%)
|
||||||||||
Rest of World
|
75.7
|
88.8
|
70.2
|
79.9
|
314.6
|
75.8
|
84.9
|
76.6
|
80.6
|
317.9
|
0.8
|
%
|
1.0
|
%
|
||||||||||
Total
|
$283.4
|
$317.1
|
$286.1
|
$318.0
|
$1,204.6
|
$291.8
|
$319.3
|
$292.9
|
$312.8
|
$1,216.8
|
(1.6
|
%)
|
1.0
|
%
|
LIVANOVA PLC
|
|||||||||
QUARTERLY SALES
|
|||||||||
U.S. dollars in millions
|
|||||||||
Three Months Ended December 31, 2016
|
|||||||||
2016
|
2015
|
% Change at Actual Currency Rates
|
% Change at Constant Currency Rates
|
||||||
Cardio Pulmonary
|
|||||||||
US
|
$41.3
|
$45.9
|
(10.0
|
%)
|
(10.0
|
%)
|
|||
Europe
|
33.8
|
35.6
|
(4.9
|
%)
|
(0.5
|
%)
|
|||
Rest of World
|
49.5
|
48.5
|
2.2
|
%
|
0.6
|
%
|
|||
Total
|
124.7
|
130.0
|
(4.0
|
%)
|
(3.4
|
%)
|
|||
Heart Valve
|
|||||||||
US
|
6.8
|
5.8
|
17.4
|
%
|
17.4
|
%
|
|||
Europe
|
10.7
|
10.9
|
(1.6
|
%)
|
1.7
|
%
|
|||
Rest of World
|
16.5
|
18.2
|
(9.6
|
%)
|
(10.6
|
%)
|
|||
Total
|
34.0
|
34.9
|
(2.6
|
%)
|
(2.2
|
%)
|
|||
Cardiac Surgery
|
|||||||||
US
|
48.1
|
51.7
|
(6.9
|
%)
|
(6.9
|
%)
|
|||
Europe
|
44.5
|
46.5
|
(4.1
|
%)
|
0.0
|
%
|
|||
Rest of World
|
66.1
|
66.7
|
(1.0
|
%)
|
(2.5
|
%)
|
|||
Total
|
158.7
|
164.9
|
(3.7
|
%)
|
(3.2
|
%)
|
|||
CRM
|
|||||||||
US
|
2.5
|
3.1
|
(20.9
|
%)
|
(20.9
|
%)
|
|||
Europe
|
48.1
|
50.5
|
(4.8
|
%)
|
(2.7
|
%)
|
|||
Rest of World
|
10.5
|
7.0
|
49.1
|
%
|
39.7
|
%
|
|||
Total
|
61.0
|
60.7
|
0.6
|
%
|
1.3
|
%
|
|||
Neuromodulation
|
|||||||||
US
|
77.6
|
76.8
|
1.0
|
%
|
1.0
|
%
|
|||
Europe
|
7.7
|
9.2
|
(15.8
|
%)
|
(8.2
|
%)
|
|||
Rest of World
|
5.2
|
5.5
|
(5.2
|
%)
|
(4.5
|
%)
|
|||
Total
|
90.5
|
91.5
|
(1.1
|
%)
|
(0.3
|
%)
|
|||
Other
|
|||||||||
US
|
—
|
—
|
N/A
|
N/A
|
|||||
Europe
|
—
|
0.2
|
N/A
|
N/A
|
|||||
Rest of World
|
0.4
|
0.7
|
(36.2
|
%)
|
(34.7
|
%)
|
|||
Total
|
0.4
|
0.9
|
(54.7
|
%)
|
(53.5
|
%)
|
|||
Total
|
|||||||||
US
|
128.1
|
131.6
|
(2.7
|
%)
|
(2.7
|
%)
|
|||
Europe
|
100.3
|
106.4
|
(5.7
|
%)
|
(2.2
|
%)
|
|||
Rest of World
|
82.2
|
79.9
|
2.8
|
%
|
0.8
|
%
|
|||
Total
|
$310.6
|
$318.0
|
(2.3
|
%)
|
(1.6
|
%)
|
|||
LIVANOVA PLC
|
|||||||||
FY16 SALES
|
|||||||||
U.S. dollars in millions
|
|||||||||
Twelve Months Ended December 31, 2016
|
|||||||||
2016
|
2015
|
% Change at Actual Currency Rates
|
% Change at Constant Currency Rates
|
||||||
Cardio Pulmonary
|
|||||||||
US
|
$154.4
|
$161.7
|
(4.5
|
%)
|
(4.5
|
%)
|
|||
Europe
|
128.5
|
137.9
|
(6.8
|
%)
|
(4.9
|
%)
|
|||
Rest of World
|
191.5
|
176.9
|
8.3
|
%
|
7.6
|
%
|
|||
Total
|
474.4
|
476.4
|
(0.4
|
%)
|
(0.1
|
%)
|
|||
Heart Valve
|
|||||||||
US
|
27.7
|
25.2
|
9.8
|
%
|
9.8
|
%
|
|||
Europe
|
44.3
|
46.9
|
(5.5
|
%)
|
(4.0
|
%)
|
|||
Rest of World
|
65.3
|
68.1
|
(4.1
|
%)
|
(4.3
|
%)
|
|||
Total
|
137.3
|
140.2
|
(2.1
|
%)
|
(1.6
|
%)
|
|||
Cardiac Surgery
|
|||||||||
US
|
182.1
|
186.9
|
(2.5
|
%)
|
(2.5
|
%)
|
|||
Europe
|
172.8
|
184.8
|
(6.5
|
%)
|
(4.7
|
%)
|
|||
Rest of World
|
256.8
|
245.0
|
4.8
|
%
|
4.3
|
%
|
|||
Total
|
611.7
|
616.6
|
(0.8
|
%)
|
(0.5
|
%)
|
|||
CRM
|
|||||||||
US
|
9.9
|
15.5
|
(36.0
|
%)
|
(36.0
|
%)
|
|||
Europe
|
197.2
|
198.6
|
(0.7
|
%)
|
0.1
|
%
|
|||
Rest of World
|
41.9
|
46.4
|
(9.7
|
%)
|
(14.7
|
%)
|
|||
Total
|
249.1
|
260.5
|
(4.4
|
%)
|
(4.7
|
%)
|
|||
Neuromodulation
|
|||||||||
US
|
298.5
|
268.8
|
11.0
|
%
|
11.0
|
%
|
|||
Europe
|
31.9
|
35.2
|
(9.2
|
%)
|
(4.9
|
%)
|
|||
Rest of World
|
21.0
|
20.3
|
3.3
|
%
|
3.6
|
%
|
|||
Total
|
351.4
|
324.3
|
8.3
|
%
|
8.8
|
%
|
|||
Other
|
|||||||||
US
|
—
|
—
|
N/A
|
N/A
|
|||||
Europe
|
0.1
|
0.3
|
N/A
|
N/A
|
|||||
Rest of World
|
1.6
|
2.9
|
(44.1
|
%)
|
(41.1
|
%)
|
|||
Total
|
1.7
|
3.2
|
(45.4
|
%)
|
(42.6
|
%)
|
|||
Total
|
|||||||||
US
|
490.5
|
471.2
|
4.1
|
%
|
4.1
|
%
|
|||
Europe
|
402.1
|
418.8
|
(4.0
|
%)
|
(2.5
|
%)
|
|||
Rest of World
|
321.4
|
314.6
|
2.1
|
%
|
1.0
|
%
|
|||
Total
|
$1,213.9
|
$1,204.6
|
0.8
|
%
|
1.0
|
%
|
|||
LIVANOVA PLC AND SUBSIDIARIES
|
||
CONSOLIDATED STATEMENT OF INCOME (LOSS)
|
||
U.S. dollars in millions, except per share amounts
|
||
Three Months Ended December 31, 2016
|
||
Net sales
|
$310.6
|
|
Cost of sales
|
111.3
|
|
Product remediation
|
35.3
|
|
Gross Profit
|
164.0
|
|
Operating expenses
|
||
Selling, general and administrative
|
123.5
|
|
Research and development
|
28.4
|
|
Merger and integration expense
|
—
|
|
Restructuring expense
|
18.7
|
|
Amortization of intangibles
|
11.6
|
|
Goodwill Impairment
|
18.3
|
|
Total operating expenses
|
200.5
|
|
Income (loss) from operations
|
(36.5
|
|
Interest income (expense), net
|
(3.4
|
|
Foreign exchange and other - gain (loss)
|
3.5
|
|
Income (loss) before income taxes
|
(36.3
|
|
Loss from equity method investments
|
(3.2
|
|
Income tax expense (benefit)
|
(9.8
|
|
Net (loss) income
|
($29.8)
|
|
Earnings (Loss) Per Common Share:
|
||
Basic
|
($0.61)
|
|
Diluted
|
($0.61)
|
|
Weighted Average Common Shares Outstanding
|
||
Basic
|
48.5
|
|
Diluted
|
48.5
|
|
Adjusted Gross Profit (1)
|
$200.1
|
|
Adjusted SG&A (1)
|
$115.0
|
|
Adjusted R&D (1)
|
$28.0
|
|
Adjusted Income from Operations (1)
|
$57.1
|
|
Adjusted Net Income (1)
|
$41.5
|
|
Adjusted Diluted Earnings Per Share (1)
|
$0.85
|
Statistics (as a % of net sales, except for income tax rate)
|
||||||||
GAAP Three Months Ended December 31,
|
Adjusted (1) Three Months Ended December 31,
|
|||||||
2016
|
2016
|
2015
|
||||||
Gross Profit
|
52.8
|
%
|
64.4
|
%
|
61.9
|
%
|
||
SG&A
|
39.8
|
%
|
37.0
|
%
|
36.8
|
%
|
||
R&D
|
9.1
|
%
|
9.0
|
%
|
11.1
|
%
|
||
Income (loss) from Operations
|
(11.7
|
%)
|
18.4
|
%
|
14.0
|
%
|
||
Net (loss) income
|
(9.6
|
%)
|
13.4
|
%
|
n/a
|
|||
Income Tax Rate
|
(26.9
|
%)
|
21.0
|
%
|
n/a
|
(1) Adjusted financial measures are Non-GAAP measures and exclude specified items as described and reconciled to compare GAAP financial
|
measures in the Reconciliation of GAAP to non-GAAP Financial Measures contained in the press release.
|
* Numbers may not add due to rounding. n/a is not applicable; there is no applicable adjusted net income or tax rate reported for 4Q15.
|
LIVANOVA PLC AND SUBSIDIARIES
|
||
CONSOLIDATED STATEMENT OF INCOME (LOSS)
|
||
U.S. dollars in millions, except per share amounts
|
||
Twelve Months Ended December 31, 2016
|
||
Net sales
|
$1,213.9
|
|
Cost of sales
|
472.0
|
|
Product remediation
|
37.5
|
|
Gross Profit
|
704.4
|
|
Operating expenses
|
||
Selling, general and administrative
|
469.2
|
|
Research and development
|
122.5
|
|
Merger and integration expense
|
20.5
|
|
Restructuring expense
|
55.9
|
|
Amortization of intangibles
|
45.5
|
|
Goodwill impairment
|
18.3
|
|
Total operating expenses
|
732.0
|
|
Income (loss) from operations
|
(27.6
|
|
Interest income (expense), net
|
(8.9
|
|
Foreign exchange and other - gain (loss)
|
3.5
|
|
Income (loss) before income taxes
|
(33.0
|
|
Loss from equity method investments
|
(22.6
|
|
Income tax expense (benefit)
|
7.1
|
|
Net (loss) income
|
($62.8)
|
|
Earnings (Loss) Per Common Share:
|
||
Basic
|
($1.29)
|
|
Diluted
|
($1.29)
|
|
Weighted Average Common Shares Outstanding
|
||
Basic
|
48.9
|
|
Diluted
|
48.9
|
|
Adjusted Gross Profit (1)
|
$784.6
|
|
Adjusted SG&A (1)
|
$445.5
|
|
Adjusted R&D (1)
|
$120.5
|
|
Adjusted Income from Operations (1)
|
$218.6
|
|
Adjusted Net Income (1)
|
$149.3
|
|
Adjusted Diluted Earnings Per Share (1)
|
$3.05
|
Statistics (as a % of net sales, except for income tax rate)
|
||||||||
GAAP Twelve Months Ended December 31,
|
Adjusted (1) Twelve Months Ended December 31,
|
|||||||
2016
|
2016
|
2015
|
||||||
Gross Profit
|
58.0
|
%
|
64.6
|
%
|
63.1
|
%
|
||
SG&A
|
38.7
|
%
|
36.7
|
%
|
36.9
|
%
|
||
R&D
|
10.1
|
%
|
9.9
|
%
|
11.9
|
%
|
||
Income (loss) from Operations
|
(2.3
|
%)
|
18.0
|
%
|
14.3
|
%
|
||
Net (loss) income
|
(5.2
|
%)
|
12.3
|
%
|
n/a
|
|||
Income Tax Rate
|
21.6
|
%
|
24.9
|
%
|
n/a
|
(1) Adjusted financial measures are Non-GAAP measures and exclude specified items as described and reconciled to compare GAAP financial
|
measures in the Reconciliation of GAAP to non-GAAP Financial Measures contained in the press release.
|
LIVANOVA PLC AND SUBSIDIARIES
|
||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
|
||||||||||
U.S. dollars in millions, except per share amounts
|
||||||||||
Three Months Ended December 31, 2016
|
Sales
|
Gross Profit
|
Income From Operations
|
Net Income (Loss)
|
Diluted EPS
|
|||||
GAAP Financial Measures
|
$310.6
|
$164.0
|
($36.5)
|
($29.8)
|
($0.61)
|
|||||
Specified Items
|
||||||||||
Merger and integration expense (A)
|
—
|
—
|
—
|
—
|
||||||
Restructuring expense (B)
|
—
|
18.7
|
12.1
|
0.25
|
||||||
Amortization of intangible assets (C)
|
0.9
|
12.9
|
13.4
|
0.27
|
||||||
Impairment of goodwill (D)
|
—
|
18.3
|
18.3
|
0.38
|
||||||
3T product remediation (E)
|
35.3
|
35.3
|
23.8
|
0.49
|
||||||
Other Income Expenses & Litigations (F)
|
—
|
4.3
|
3.6
|
0.07
|
||||||
Impact of inventory step-up (G)
|
—
|
—
|
—
|
—
|
||||||
Equity compensation (H)
|
(0.1
|
)
|
4.0
|
1.7
|
0.03
|
|||||
Certain tax adjustments (I)
|
—
|
—
|
(1.6
|
)
|
(0.03
|
)
|
||||
Adjusted financial measures
|
$310.6
|
$200.1
|
$57.1
|
$41.5
|
$0.85
|
|||||
GAAP results for the three months ended December 31, 2016 include:
|
||||||||||
(A)
|
Expenses related to merger and integration activities
|
|||||||||
(B)
|
Corporate-related severance, shared-service synergies and recent organizational changes
|
|||||||||
(C)
|
Amortization expense associated with intangible assets recorded at fair value in purchase accounting
|
|||||||||
(D)
|
Impairment of CRM segment goodwill
|
|||||||||
(E)
|
Costs related to the 3T Heater-Cooler Remediation Plan
|
|||||||||
(F)
|
Cost of $2.6M related to the reassessment of earn-out provisions for two legacy distributor acquisitions; $0.7M related to a provision for a tax penalty for previous years under audit in a foreign jurisdiction
|
|||||||||
(G)
|
Includes amortization of inventory step-up associated with purchase accounting
|
|||||||||
(H)
|
Includes $4.0M related to SG&A, $0.1M related to R&D, and $0.1M related to Cost of Sales
|
|||||||||
(I)
|
Relates to the impact of restructuring initiatives, including IP migration
|
|||||||||
Twelve Months Ended December 31, 2016
|
Sales
|
Gross Profit
|
Income From Operations
|
Net Income (Loss)
|
Diluted EPS
|
|||||
GAAP Financial Measures
|
$1,213.9
|
$704.4
|
($27.6)
|
($62.8)
|
($1.29)
|
|||||
Specified Items
|
||||||||||
Merger and integration expense (A)
|
—
|
20.5
|
14.6
|
0.30
|
||||||
Restructuring expense (B)
|
—
|
55.9
|
45.5
|
0.93
|
||||||
Amortization of intangible assets (C)
|
6.8
|
52.4
|
42.5
|
0.87
|
||||||
Impairment of goodwill (D)
|
—
|
18.3
|
18.3
|
0.37
|
||||||
3T product remediation (E)
|
37.5
|
37.5
|
24.8
|
0.51
|
||||||
Other Income Expenses & Litigations (F)
|
—
|
6.9
|
4.7
|
0.10
|
||||||
Write-off of investment in minorities (G)
|
—
|
—
|
9.2
|
0.19
|
||||||
Impact of inventory step-up (H)
|
35.2
|
35.2
|
26.3
|
0.54
|
||||||
Equity compensation (I)
|
0.7
|
19.3
|
14.5
|
0.30
|
||||||
Certain tax adjustments (J)
|
—
|
—
|
11.4
|
0.23
|
||||||
Adjusted financial measures
|
$1,213.9
|
$784.6
|
$218.6
|
$149.3
|
$3.05
|
|||||
GAAP results for the twelve months ended December 31, 2016 include:
|
||||||||||
(A)
|
Expenses related to merger and integration activities
|
|||||||||
(B)
|
CRM restructuring announced March 10, 2016, corporate-related severance, shared-service synergies and recent organizational changes
|
|||||||||
(C)
|
Amortization expense associated with intangible assets recorded at fair value in purchase accounting
|
|||||||||
(D)
|
Impairment of CRM segment goodwill
|
|||||||||
(E)
|
Costs related to the 3T Heater-Cooler Remediation Plan
|
|||||||||
(F)
|
Includes a gain recognized for the reimbursement of $4.7M of earthquake damages incurred in Mirandola (Italy) in 2012; $5.0M for the reserve of certain receivables from a Greece distributor; $2.6M related to the reassessment of earn-out provisions for two legacy distributor acquisitions; $0.8M related litigation settlements with two independent sales agent; $0.7M related to accruals for tax penalties related to previous years; $2.5M related to other litigation
|
|||||||||
(G)
|
$9.2M related to the impairment of a purchase option for Respicardia
|
|||||||||
(H)
|
Includes amortization of inventory step-up associated with purchase accounting
|
|||||||||
(I)
|
Includes $17.7M related to SG&A, $0.9M related to R&D, and $0.7M related to Cost of Sales
|
J)
|
Relates to the impact of restructuring initiatives, including IP migration
|
LIVANOVA PLC AND SUBSIDIARIES
|
||||
CONDENSED CONSOLIDATED BALANCE SHEETS
|
||||
U.S. dollars in millions
|
||||
December 31, 2016
|
December 31, 2015
|
|||
ASSETS
|
(Unaudited)
|
|||
Current Assets:
|
||||
Cash and cash equivalents
|
$39.8
|
$112.6
|
||
Short-term investments
|
—
|
7.0
|
||
Accounts receivable, net
|
275.7
|
272.4
|
||
Inventories
|
183.5
|
212.4
|
||
Prepaid and refundable income taxes
|
60.6
|
42.4
|
||
Prepaid expenses and other current assets
|
60.5
|
26.6
|
||
Total Current Assets
|
620.1
|
673.4
|
||
Property, plant and equipment, net
|
223.8
|
244.6
|
||
Goodwill
|
691.7
|
745.4
|
||
Intangible assets, net
|
609.2
|
658.9
|
||
Investments
|
61.1
|
77.5
|
||
Deferred tax assets net
|
6.0
|
153.5
|
||
Other assets
|
130.7
|
5.4
|
||
Total Assets
|
$2,342.6
|
$2,558.7
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||
Current Liabilities:
|
||||
Current debt obligations
|
$47.7
|
$82.5
|
||
Accounts payable
|
93.0
|
109.6
|
||
Accrued liabilities
|
75.6
|
63.0
|
||
Income taxes payable
|
22.3
|
26.7
|
||
Accrued employee compensation and related benefits liability
|
78.3
|
77.3
|
||
Total Current Liabilities
|
316.8
|
359.1
|
||
Long-term debt obligations
|
75.2
|
91.8
|
||
Deferred income taxes liability
|
172.5
|
235.5
|
||
Long-term employee compensation and related benefits liability
|
31.7
|
31.1
|
||
Other long-term liabilities
|
39.5
|
29.7
|
||
Total Liabilities
|
635.7
|
747.3
|
||
Total Stockholders' Equity
|
1,706.9
|
1,811.5
|
||
Total Liabilities and Stockholders' Equity
|
$2,342.6
|
$2,558.7
|
LIVANOVA PLC AND SUBSIDIARIES
|
||||
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW
|
||||
U.S. dollars in millions
|
||||
(Unaudited)
|
||||
Twelve Months Ended December 31st, 2016
|
||||
Cash Flows from Operating Activities:
|
||||
Net (loss) Income
|
($62.8)
|
|||
Non-cash items included in net (loss) income :
|
||||
Depreciation
|
39.9
|
|||
Amortization
|
45.5
|
|||
Stock-based compensation
|
19.6
|
|||
Amortization of prepaid income taxes on intercompany transfers
|
26.0
|
|||
Deferred income tax (benefit) expense
|
(26.7
|
)
|
||
Impairment of goodwill
|
18.3
|
|||
Impairment of property, plant and equipment
|
6.0
|
|||
Loss from equity method investments
|
22.6
|
|||
Other
|
10.2
|
|||
Changes in operating assets and liabilities:
|
||||
Accounts receivable, net
|
(16.4
|
)
|
||
Inventories
|
26.7
|
|||
Other current and non-current assets
|
(32.7
|
)
|
||
Restructuring reserve
|
12.4
|
|||
Accounts payable and accrued current and non-current liabilities
|
1.6
|
|||
Net cash provided by operating activities
|
90.2
|
|||
Cash Flow from Investing Activities:
|
||||
Purchase of short-term investments
|
(7.1
|
)
|
||
Maturities of short-term investments
|
14.1
|
|||
Purchase of property, plant and equipment
|
(35.3
|
)
|
||
Intangible assets purchases
|
(1.9
|
)
|
||
Purchase of Equity and Cost Method Investments
|
(8.0
|
)
|
||
Net cash used in investing activities
|
(38.2
|
)
|
||
Cash Flow From Financing Activities:
|
||||
Short-term borrowing (repayments) borrowing, net
|
(33.7
|
)
|
||
Proceeds from long term debt obligations
|
7.2
|
|||
Repayment of long-term debt obligations
|
(21.1
|
)
|
||
Repayment of trade receivable advances
|
(23.8
|
)
|
||
Loans to equity method investees
|
(6.3
|
)
|
||
Proceeds from exercise of options for stock
|
8.3
|
|||
Realized excess tax benefits - stock based compensation
|
2.1
|
|||
Share repurchases
|
(54.5
|
)
|
||
Cash settlement of compensation-based stock units
|
(2.7
|
)
|
||
Other financial assets and liabilities
|
0.1
|
|||
Net cash used in financing activities
|
(124.3
|
)
|
||
Effect of exchange rate changes on cash and cash equivalents
|
(0.4
|
)
|
||
Net decrease in cash and cash equivalents
|
(72.8
|
)
|
||
Cash and cash equivalents at beginning of period
|
112.6
|
|||
Cash and cash equivalents at end of period
|
$39.8
|
|||
*
|
Numbers may not add due to rounding.
|
|||
Supplementary disclosure of Cash Flow Information:
|
||||
Cash paid for interest
|
7.4
|
|||
Cash paid for income taxes
|
47.8
|